XRCC4 and cancer: We previously demonstrated that ABCB1 inhibition re-sensitizes p53null SKOV3 to anti-cancer drugs by recruiting a critical factor of the non-homologous end-joining DNA repair pathway, XRCC4, resulting in the activation of DNA repair activity and reduction of cellular proliferation [16].